{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:34:26Z","timestamp":1793270066463,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hrthm.2026.10.007","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:56:41Z","timestamp":1792079801000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First use of empagliflozin to treat a patient with congenital long QT syndrome type III."],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8791-1162","authenticated-orcid":false,"given":"Ehud","family":"Chorin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roei","family":"Merin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Giladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Banai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Viskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2026.10.007_bib1","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(99)02107-8","article-title":"The long QT syndromes and torsade de pointes","volume":"354","author":"Viskin","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2026.10.007_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(08)61307-0","article-title":"The QT syndromes: long and short","volume":"372","author":"Morita","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2026.10.007_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI0215928","article-title":"Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome","volume":"110","author":"Clancy","year":"2002","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.hrthm.2026.10.007_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0735-1097(99)00582-3","article-title":"Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome","volume":"35","author":"Shimizu","year":"2000","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib5","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.jacc.2009.12.015","article-title":"The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome","volume":"55","author":"Viskin","year":"2010","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1161\/CIRCULATIONAHA.105.600445","article-title":"Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response","volume":"113","author":"Vyas","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.10.007_bib7","first-page":"273","article-title":"Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congential long QT syndrome","volume":"3","author":"Shimizu","year":"2004","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.10.007_bib8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1540-8167.2004.03096.x","article-title":"Heart rate dependence of the QT interval duration: differences among congenital long QT syndrome subtypes","volume":"15","author":"Nemec","year":"2004","journal-title":"J. Cardiovasc. Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004370","article-title":"Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data","volume":"9","author":"Chorin","year":"2016","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib10","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/CIRCULATIONAHA.106.642694","article-title":"Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications","volume":"114","author":"Tan","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.10.007_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/01.CIR.103.1.89","article-title":"Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias","volume":"103","author":"Schwartz","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.10.007_bib12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1056\/NEJM199810013391404","article-title":"Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group","volume":"339","author":"Zareba","year":"1998","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.hrthm.2026.10.007_bib13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jama.292.11.1341","article-title":"Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers","volume":"292","author":"Priori","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.hrthm.2026.10.007_bib14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.116.021823","article-title":"Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study","volume":"134","author":"Wilde","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.10.007_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/europace\/euw439","article-title":"Long-term flecainide therapy in type 3 long QT syndrome","volume":"20","author":"Chorin","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2026.10.007_bib16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2015.12.033","article-title":"Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3","volume":"67","author":"Mazzanti","year":"2016","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium\/Glucose Cotransporter 2 Inhibitor Empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.10.007_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1098-1004(1998)12:1<72::AID-HUMU17>3.0.CO;2-Z","article-title":"Identification of a new SCN5A mutation, D1840G, associated with the long QT syndrome. Mutations in brief no. 153. Online","volume":"12","author":"Benhorin","year":"1998","journal-title":"Hum. Mutat"},{"key":"10.1016\/j.hrthm.2026.10.007_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000437089","article-title":"Novel Clinical Manifestation of the Known SCN5A D1790G Mutation","volume":"132","author":"Blich","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.hrthm.2026.10.007_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1540-8159.2009.02190.x","article-title":"Is flecainide dangerous in long QT-3 patients? Pacing Clin","volume":"32","author":"Beinart","year":"2009","journal-title":"Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/eurheartj\/ehaa041","article-title":"Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine","volume":"41","author":"Postema","year":"2020","journal-title":"Eur. Heart J"},{"key":"10.1016\/j.hrthm.2026.10.007_bib23","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00392-024-02383-9","article-title":"Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias","volume":"113","author":"Alhourani","year":"2024","journal-title":"Clin. Res. Cardiol"},{"key":"10.1016\/j.hrthm.2026.10.007_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.yjmcc.2024.11.014","article-title":"The sodium\/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner","volume":"198","author":"Lunsonga","year":"2025","journal-title":"J. Mol. Cell. Cardiol"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126028687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126028687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:53:28Z","timestamp":1793267608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527126028687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"alternative-id":["S1547527126028687"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.10.007","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First use of empagliflozin to treat a patient with congenital long QT syndrome type III.","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of Heart Rhythm Society.","name":"copyright","label":"Copyright"}]}}